Shukra Pharmaceuticals Ltd

Shukra Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 17 Jul 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 March 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Shukra Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 17 Jul 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 09 March 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing.

Shukra Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 17 July 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 February 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Shukra Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 17 July 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 13 February 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing.

Shukra Pharmaceuticals Ltd. delivered a dramatic turnaround in Q3 FY26, posting net profit of ₹20.36 crores—a staggering 755.46% surge from the previous quarter's ₹2.38 crores. The micro-cap pharmaceutical company, with a market capitalisation of ₹1,723 crores, reported revenues of ₹39.13 crores for the quarter ended December 2025, representing an extraordinary 565.48% sequential growth. However, the stock has retreated 1.84% to ₹38.88 following the results, reflecting investor caution over the company's stretched valuation multiples.

Shukra Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 17 July 2025. While this rating change occurred several months ago, the analysis and financial metrics discussed here reflect the company’s current position as of 02 February 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.

Shukra Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 17 Jul 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 22 January 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Shukra Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 17 Jul 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 11 January 2026, providing investors with the latest insights into its performance and outlook.

Shukra Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, with a recent downgrade in its Mojo Grade from Sell to Hold signalling a cautious optimism among investors. Despite a sharp 4.99% decline in the latest trading session, the stock’s long-term returns remain impressive, though mixed technical indicators suggest a complex near-term outlook.

Shukra Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 17 Jul 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 31 December 2025, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook.

Shukra Pharmaceuticals Ltd has witnessed a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. Despite some bearish signals on momentum oscillators like RSI, the overall technical landscape, including MACD and moving averages, suggests strengthening price action. This article analyses the recent technical developments, price performance, and what investors might expect going forward.

Shukra Pharmaceuticals has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across key indicators. While the stock’s price momentum shows signs of mild bullishness, certain oscillators and trend analyses suggest caution, underscoring the importance of a balanced view for investors navigating the Pharmaceuticals & Biotechnology sector.

Shukra Pharma., a microcap player in the Pharmaceuticals & Biotechnology sector, has undergone a revision in its market evaluation reflecting a nuanced shift in its financial and technical outlook. This change comes amid a backdrop of strong stock returns contrasted by recent operational challenges and valuation concerns.

Shukra Pharmaceuticals has reached a significant milestone by touching a new 52-week high of Rs.65.26, marking a notable phase of momentum in the Pharmaceuticals & Biotechnology sector. This achievement reflects a sustained upward trend supported by strong market dynamics and consistent gains over recent weeks.

Shukra Pharmaceuticals has reached a new all-time high of Rs. 65.26, marking a significant milestone in its market journey. The stock’s performance over recent months reflects sustained momentum within the Pharmaceuticals & Biotechnology sector, outpacing key benchmarks and demonstrating robust investor confidence.